Total Lifetime and Cancer-related Costs for Elderly Patients Diagnosed With Anal Cancer in the United States.
Total Lifetime and Cancer-related Costs for Elderly Patients Diagnosed With Anal Cancer in the United States.
复制标题
DOI：
10.1097/coc.0000000000000238
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Cantor SB
中科院分区：
文献类型：
--
作者：
Deshmukh AA;Zhao H;Franzini L;Lairson DR;Chiao EY;Das P;Swartz MD;Giordano SH;Cantor SB
To determine the lifetime and phase-specific cost of anal cancer management and the economic burden of anal cancer care in elderly (≥66 years) patients in the United States. For this study, we used Surveillance Epidemiology and End Results-Medicare linked database (1992–2009). We matched newly diagnosed anal cancer patients (by age and sex) to non-cancer controls. We estimated survival time from the date of diagnosis until death. Lifetime and average annual cost by stage and age at diagnosis were estimated by combining survival data with Medicare claims. The average lifetime cost, proportion of patients who were elderly, and the number of incident cases were used to estimate the economic burden. The average lifetime cost for patients with anal cancer was US$50,150 (N=2,227) (2014 US dollars). The average annual cost in men and women was US$8,025 and US$5,124, respectively. The overall survival after the diagnosis of cancer was 8.42 years. As the age and stage at diagnosis increased, so did the cost of cancer-related care. The anal cancer-related lifetime economic burden in Medicare patients in the US was US$112 million. Although the prevalence of anal cancer among the elderly in the United States is small, its economic burden is considerable.
